ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 143 filers reported holding ASCENDIS PHARMA A/S in Q1 2019. The put-call ratio across all filers is 0.49 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $2,885,000 | -71.7% | 18,100 | -76.6% | 0.13% | -69.8% |
| Q2 2021 | $10,189,000 | -2.9% | 77,450 | -4.9% | 0.42% | -5.4% |
| Q1 2021 | $10,497,000 | -34.1% | 81,450 | -14.7% | 0.44% | -40.3% |
| Q4 2020 | $15,919,000 | -10.6% | 95,450 | -17.3% | 0.74% | -13.4% |
| Q3 2020 | $17,816,000 | -7.7% | 115,450 | -11.5% | 0.86% | +3.7% |
| Q2 2020 | $19,294,000 | +13.9% | 130,450 | -13.3% | 0.83% | +7.0% |
| Q1 2020 | $16,942,000 | -55.0% | 150,450 | -44.4% | 0.78% | -41.7% |
| Q4 2019 | $37,625,000 | +25.8% | 270,450 | -12.9% | 1.33% | +30.4% |
| Q3 2019 | $29,903,000 | -66.2% | 310,450 | -59.6% | 1.02% | -62.2% |
| Q2 2019 | $88,457,000 | -25.5% | 768,193 | -23.8% | 2.70% | -19.0% |
| Q1 2019 | $118,664,000 | +87.9% | 1,008,193 | 0.0% | 3.33% | +59.8% |
| Q4 2018 | $63,163,000 | +13.3% | 1,008,193 | +28.2% | 2.08% | +13.1% |
| Q3 2018 | $55,731,000 | +86.0% | 786,493 | +74.6% | 1.84% | +86.0% |
| Q2 2018 | $29,969,000 | – | 450,526 | – | 0.99% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |